- Home
- ASRV vs BTAI Comparison
ASRV vs BTAI Comparison
Compare ASRV & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRV
- BTAI
- Stock Information
- Founded
- ASRV 1983
- BTAI 2017
- Country
- ASRV United States
- BTAI United States
- Employees
- ASRV N/A
- BTAI N/A
- Industry
- ASRV Major Banks
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ASRV Finance
- BTAI Health Care
- Exchange
- ASRV Nasdaq
- BTAI Nasdaq
- Market Cap
- ASRV 46.7M
- BTAI 52.7M
- IPO Year
- ASRV N/A
- BTAI 2018
- Fundamental
- Price
- ASRV $2.95
- BTAI $3.06
- Analyst Decision
- ASRV
- BTAI Buy
- Analyst Count
- ASRV 0
- BTAI 5
- Target Price
- ASRV N/A
- BTAI $32.80
- AVG Volume (30 Days)
- ASRV 7.6K
- BTAI 5.2M
- Earning Date
- ASRV 10-21-2025
- BTAI 11-13-2025
- Dividend Yield
- ASRV 4.10%
- BTAI N/A
- EPS Growth
- ASRV N/A
- BTAI N/A
- EPS
- ASRV 0.22
- BTAI N/A
- Revenue
- ASRV $51,581,000.00
- BTAI $868,000.00
- Revenue This Year
- ASRV N/A
- BTAI N/A
- Revenue Next Year
- ASRV N/A
- BTAI $614.78
- P/E Ratio
- ASRV $13.79
- BTAI N/A
- Revenue Growth
- ASRV 13.95
- BTAI N/A
- 52 Week Low
- ASRV $2.03
- BTAI $1.17
- 52 Week High
- ASRV $3.42
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- ASRV 49.39
- BTAI 42.64
- Support Level
- ASRV $2.80
- BTAI $2.86
- Resistance Level
- ASRV $3.07
- BTAI $3.95
- Average True Range (ATR)
- ASRV 0.10
- BTAI 0.34
- MACD
- ASRV 0.00
- BTAI -0.17
- Stochastic Oscillator
- ASRV 50.00
- BTAI 16.43
About ASRV AmeriServ Financial Inc.
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.